Domestic pharmaceutical companies have broken the Sevikar patent, giving generics positive signs

Domestic pharmaceutical companies have succeeded in breaking the Sevikar patent.

According to the Intellectual Property Tribunal, 3 pharmaceutical companies, such as Korea United Pharm, JW Pharmaceutical and JRP, have completely nullified the patent of the Daiichi-Sankyo’s hypertension complex, Sevikar(Amlodipine+Olmesartan), completely.

The use patent of Sevikar is scheduled to be expired in...